Bristol-Myers Squibb Company
TREATMENT OF HODGKIN LYMPHOMA USING AN ANTI-PD-1 ANTIBODY

Abstract:

This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody to a subject, wherein the subject has received at least one prior treatment for Hodgkin lymphoma.